ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
iSERA Lifesciences will not comply with Regulation 23(9) for the half year ended 30 September 2026. Its capital and net worth are below exemption thresholds.
iSERA Lifesciences Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
iSERA Lifesciences gave notice of a board meeting on November 4, 2026 to consider standalone unaudited results for the quarter and half year ended September 30, 2026. The filing also notes the trading window closure from October 1, 2026.
iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Promoters and directors of iSERA Lifesciences acquired shares through a preferential offer valued at ₹113.98 Crore. This transaction changes the company's capital structure.
Promoter Pratap Dadasaheb Deshmukh acquired 86.13 lakh shares via preferential allotment. His stake in iSERA Lifesciences shifted to 55.07% following the company's capital restructuring.
iSERA Lifesciences Limited approved the allotment of 1,61,82,800 equity shares on a preferential basis. The allotment, priced at Rs. 48.20 per share, total Rs. 78.00 Crore.
iSERA Lifesciences Limited conducted its 34th Annual General Meeting on 29th September 2026, where shareholders adopted the audited financial statements and re-appointed a director.